Anthracyclines are a class of antibiotics derived from streptomycetes, which have been widely used in the treatment of various types of cancer due to their potent antitumor activity. These compounds exhibit remarkable efficacy against solid tumors and hematological malignancies through multiple mechanisms, including intercalation into DNA, generation of free radicals leading to cell death, and inhibition of topoisomerase II enzymes. Common anthracyclines include doxorubicin, daunorubicin, and epirubicin, each with its own specific characteristics in terms of efficacy and toxicity profiles. The clinical application of anthracyclines is extensive but must be carefully managed due to potential side effects such as cardiotoxicity, which can result in heart failure. Regular monitoring of cardiac function is essential for patients undergoing treatment with these drugs. Additionally, dose adjustment or the use of cardioprotective agents may be necessary to mitigate risks associated with their administration. These powerful chemotherapeutic agents continue to play a critical role in cancer therapy, offering hope to millions of patients worldwide despite ongoing challenges and limitations.